Claims
- 1. A kit for detecting the presence of the expression of a leukemia associated polypeptide precursor comprising a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of SEQ ID NO:1, (b) a 12-32 nucleotide contiguous segment of SEQ ID NO:3, (c) a 12-32 nucleotide contiguous segment of SEQ ID NO:5, (d) a 12-32 nucleotide contiguous segment of SEQ ID NO:7, (e) complements of “(a)”, (f) complements of “(b)”, (g) complements of “(c)”,and (h) complements of “(d)”, wherein the contiguous segments are nonoverlapping.
- 2. The kit of claim 1, a wherein the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify at least a portion of an isolated nucleic acid molecule molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7.
- 3. The kit of claim 1 wherein the pair of isolated nucleic acid molecules is PCR primers, wherein one of the primers is a contiguous segment of SEQ ID NO:1 and another of the primers is the complement of a contiguous segment of SEQ ID NO:1.
- 4. The kit of claim 1 wherein the pair of isolated nucleic acid molecules is PCR primers, wherein one of the primers is a contiguous segment of SEQ ID NO:3 and another of the primers is the complement of a contiguous segment of SEQ ID NO:3.
- 5. The kit of claim 1 wherein the pair of isolated nucleic acid molecules is PCR primers, wherein one of the primers is a contiguous segment of SEQ ID NO:5 and another of the primers is the complement of a contiguous segment of SEQ ID NO:5.
- 6. The kit of claim 1 wherein the pair of isolated nucleic acid molecules is PCR primers, wherein one of the primers is a contiguous segment of SEQ ID NO:7 and another of the primers is the complement of a contiguous segment of SEQ ID NO:7.
- 7. An isolated nucleic acid molecule selected from the group consisting of:(a) nucleic acid molecules selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:5, which code for a tryptase-L leukemia associated polypeptide, (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and (c) complements of (a) and (b).
- 8. The isolated nucleic acid molecule of claim 7, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:3 or SEQ ID NO:5.
- 9. An expression vector comprising the isolated nucleic acid molecule of claim 7 operably linked to a promoter.
- 10. A host cell transformed or transfected with the expression vector of claim 9.
- 11. An isolated nucleic acid molecule selected from the group consisting of:(a) a fragment of nucleotides 487-1499 of SEQ ID NO:3 between 12 and 1012 nucleotides in length, (b) a fragment of nucleotides 487-1499 of SEQ ID NO:5 between 12 and 1012 nucleotides in length, (c) a fragment of nucleotides 1665-1774 of SEQ ID NO:5 between 12 and 109 nucleotides in length, and (d) complements of (a), (b), and (c).
- 12. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 14 contiguous nucleotides.
- 13. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 15 contiguous nucleotides.
- 14. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 16 contiguous nucleotides.
- 15. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 17 contiguous nucleotides.
- 16. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 18 contiguous nucleotides.
- 17. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 20 contiguous nucleotides.
- 18. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is at least 22 contiguous nucleotides.
- 19. The isolated nucleic acid molecule of claim 11, wherein the isolated nucleic acid molecule is between 12 and 32 contiguous nucleotides.
Parent Case Info
This application is a divisional of application Ser. No. 09/206,537, filed Dec. 7, 1998, entitled LEUKEMIA ASSOCIATED GENES, and now pending, which is a divisional of application Ser. No. 08/845,998, filed Apr. 25, 1997, entitled LEUKEMIA ASSOCIATED GENES and now U.S. Pat. No. 5,879,892.
US Referenced Citations (7)
Number |
Name |
Date |
Kind |
5342774 |
Boon et al. |
Aug 1994 |
|
5405940 |
Boon et al. |
Apr 1995 |
|
5571711 |
van der Bruggen et al. |
Nov 1996 |
|
5587289 |
Lurquin |
Dec 1996 |
|
5589334 |
Coulie et al. |
Dec 1996 |
|
5610013 |
Van den Eynde et al. |
Mar 1997 |
|
5620886 |
Brichard et al. |
Apr 1997 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
PCTUS9204354 |
May 1992 |
WO |
PCTUS9512117 |
Nov 1996 |
WO |
Non-Patent Literature Citations (11)
Entry |
Vanderslice et al., PNAS, vol. 87, May 1990, pp. 3811-3815.* |
Traversari et al., J. Exp. Med. 176:1453-1457 (1992). |
van der Bruggen et al., Science 254:1643 (1991). |
DePlaen et al., Immunogenetics 40:360-369. |
Wilber, Clin. Endocr. 59:3 (1984). |
Bhargava et al., Proc. Natl. Acad. Sci. USA 90:10260-10264 (1993). |
Vanderslice et al., Proc. Natl. Acad. Sci. USA 87:3811-3815 (1990). |
Yanada et al., Mol. Endocrinol. 4:551-556 (1990). |
Miller et al., J. Clin. Invest. 84:1188-1195 (1989). |
Chambost et al., Brit. J. Haematology 84:524-526 (1993). |
International Search Report for International Application PCT/US98/07784. |